Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nintedanib + dextromethorphan
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital of Wenzhou Medical University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nintedanib + dextromethorphan is a combination therapy being investigated for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR 1-3), platelet-derived growth factor receptors (PDGFR α and β), and fibroblast growth factor receptors (FGFR 1-3). By inhibiting these pathways, nintedanib reduces the proliferation, migration, and transformation of fibroblasts, which are key drivers of lung fibrosis. Dextromethorphan, a morphinan derivative and NMDA receptor antagonist/sigma-1 receptor agonist, is included in the regimen to address chronic cough, a common and debilitating symptom of IPF. This combination is currently being evaluated in Phase 2 clinical trials sponsored by the First Affiliated Hospital of Wenzhou Medical University to determine if the addition of dextromethorphan can improve patient outcomes and quality of life compared to nintedanib monotherapy.
- Other names
- nidanib + dextromethorphan
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)NMDAR (Glutamate receptor ionotropic, NMDA)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)SIGMAR1 (Sigma non-opioid intracellular receptor 1)
Beyond the preview
Go deeper on nintedanib + dextromethorphan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nintedanib + dextromethorphan.